Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat

Benredjem, 2016, Analyzing biased responses of GPCR ligands, Curr. Opin. Pharmacol., 32, 71, 10.1016/j.coph.2016.11.008

Bologna, 2017, Biased G protein-coupled receptor signaling: new player in modulating physiology and pathology, Biomol. Ther., 25, 12, 10.4062/biomolther.2016.165

Butelman, 2016, Discriminative stimulus properties of opioid ligands: progress and future directions, Curr. Top. Behav. Neurosci., 1

Colpaert, 1999, Drug discrimination in neurobiology, Pharmacol. Biochem. Behav., 64, 337, 10.1016/S0091-3057(99)00047-7

Gauvin, 2016, Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: does the scientific literature support recent recommendations?, Drug Alcohol Depend., 168, 307, 10.1016/j.drugalcdep.2016.08.013

Higgins, 2001, Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function, Neuropharmacology, 41, 97, 10.1016/S0028-3908(01)00048-X

Kotlinska, 2003, Non-peptidergic OP4 receptor agonist inhibits morphine antinociception but does not influence morphine dependence, Neuroreport, 14, 601, 10.1097/00001756-200303240-00015

Linz, 2014, Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist, J. Pharmacol. Exp. Ther., 349, 535, 10.1124/jpet.114.213694

Recker, 2004, J. Pharmacol. Exp. Ther., 311, 652, 10.1124/jpet.104.071423

Rizzi, 2016, Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist, Pharmacol. Res. Perspect., 4, 1, 10.1002/prp2.247

Rutten, 2010, Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats, Eur. J. Pharmacol., 645, 119, 10.1016/j.ejphar.2010.07.036

Saccone, 2016, Characterization of the discriminative stimulus effects of a NOP receptor agonist Ro64-6198 in Rhesus monkeys, J. Pharmacol. Exp. Ther., 357, 17, 10.1124/jpet.115.231134

Siuda, 2017, Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics, Curr. Opin. Pharmacol., 32, 77, 10.1016/j.coph.2016.11.007

Sukhtankar, 2014, Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats, Eur. J. Pharmacol., 745, 182, 10.1016/j.ejphar.2014.10.029

Toll, 2016, Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems, Pharmacol. Rev., 68, 419, 10.1124/pr.114.009209

Tzschentke, 2007, (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties, J. Pharmacol. Exp. Ther., 323, 265, 10.1124/jpet.107.126052

Williams, 2013, Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance, Pharmacol. Rev., 65, 223, 10.1124/pr.112.005942

Yang, 2011, Antinociceptive potentiation and attenuation of tolerance by intrathecal β-arrestin 2 small interfering RNA in rats, Br. J. Anaesth., 107, 774, 10.1093/bja/aer291